Article(id=1329869478474658181, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869401546928487, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2023.01.001, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1669564800000, receivedDateStr=2022-11-28, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794995191447, onlineDateStr=2026-11-18, pubDate=1673280000000, pubDateStr=2023-01-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794995191447, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794995191447, creator=13701087609, updateTime=1794995191447, updator=13701087609, issue=Issue{id=1329869401546928487, tenantId=1146029695717560320, journalId=1319690329412173987, year='2023', volume='44', issue='1', pageStart='1', pageEnd='100', issueExtLink='null', onlineDate='null', pubDate='1673280000000', pubDateStr='2023-01-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794995173107, creator='13701087609', updateTime=1794995764620, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329871882981060993, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869401546928487, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329871882981060994, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329869401546928487, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1, endPage=7, ext={EN=ArticleExt(id=1329869478684373382, articleId=1329869478474658181, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress on glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a novel hypoglycemic agent with a variety of targets. It is widely used in the treatment of diabetic nephropathy (DN), which is characterized by improving oxidative stress and anti-inflammatory effects, alleviating damage of advanced glycosylation end-products, regulating renin-angiotensin-aldosterone system, improving endothelial function, alleviating renal fibrosis, and playing a protective role in the kidney. This paper reviewed the literatures published in recent years on the clinical application and mechanism of GLP-1RA in the treatment of DN, so as to provide reference for clinical practice.

, authors=Yi ZHU1, 2, Dingkun GUI2, Niansong WANG2, *, authorsList=Yi ZHU, Dingkun GUI, Niansong WANG, authorCompany=null, correspAuthors=Niansong WANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329869478948614535, articleId=1329869478474658181, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=胰高血糖素样肽-1受体激动剂治疗糖尿病肾病研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)是一种新型降糖药物,作用靶点多样,可改善氧化应激、抗炎、减轻晚期糖基化终末产物损害、调节肾素-血管紧张素-醛固酮系统、改善内皮功能以及减轻肾纤维化等,并发挥肾脏保护作用,在临床上被应用于糖尿病肾病(diabetic nephropathy,DN)的治疗。现就近年来发表的关于GLP-1RA治疗DN的临床应用和作用机制的文献进行综述,为临床提供参考。

, authors=朱轶1, 2, 桂定坤2, 汪年松2, *, authorsList=朱轶, 桂定坤, 汪年松, authorCompany=null, correspAuthors=汪年松, authorNote=

朱轶,主治医师,博士研究生,研究方向:中西医结合。

, correspAuthorsNote=
汪年松,主任医师,教授,博士研究生导师,研究方向:糖尿病肾脏疾病、急性肾损伤的发病机制和防治。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=3ROva4ci7b+fcHxNsVi9DA==, magXml=iWeXrITAbtLe0vU2ptPahg==, pdfUrl=null, pdf=7X2LU8xoRoX86WeBP/WeZA==, pdfFileSize=1560954, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=/E7ZxmeT72UG7Vn4JCR6cA==, mapNumber=null, fund=null)}, authors=[Author(id=1329869479477096847, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869479560982930, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, authorId=1329869479477096847, language=EN, stringName=Yi ZHU, firstName=Yi, middleName=null, lastName=ZHU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.Macao University of Science and Technology, Macao 999078, China
2.Department of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital, Shanghai 200233, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869479640674707, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, authorId=1329869479477096847, language=CN, stringName=朱轶, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.澳门科技大学,澳门 999078
2.上海交通大学附属上海市第六人民医院肾脏内科,上海 200233, bio={"content":"

朱轶,主治医师,博士研究生,研究方向:中西医结合。

"}, bioImg=null, bioContent=

朱轶,主治医师,博士研究生,研究方向:中西医结合。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869479275770248, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, xref=1., ext=[AuthorCompanyExt(id=1329869479305130377, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479275770248, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Macao University of Science and Technology, Macao 999078, China), AuthorCompanyExt(id=1329869479313518986, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479275770248, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.澳门科技大学,澳门 999078)]), AuthorCompany(id=1329869479397405067, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, xref=2., ext=[AuthorCompanyExt(id=1329869479401599372, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479397405067, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital, Shanghai 200233, China), AuthorCompanyExt(id=1329869479409987981, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479397405067, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海交通大学附属上海市第六人民医院肾脏内科,上海 200233)])]), Author(id=1329869479711977877, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869479925887383, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, authorId=1329869479711977877, language=EN, stringName=Dingkun GUI, firstName=Dingkun, middleName=null, lastName=GUI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital, Shanghai 200233, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869480068493720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, authorId=1329869479711977877, language=CN, stringName=桂定坤, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海交通大学附属上海市第六人民医院肾脏内科,上海 200233, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869479397405067, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, xref=2., ext=[AuthorCompanyExt(id=1329869479401599372, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479397405067, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital, Shanghai 200233, China), AuthorCompanyExt(id=1329869479409987981, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479397405067, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海交通大学附属上海市第六人民医院肾脏内科,上海 200233)])]), Author(id=1329869480173351322, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869480290791836, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, authorId=1329869480173351322, language=EN, stringName=Niansong WANG, firstName=Niansong, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital, Shanghai 200233, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869480370483613, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, authorId=1329869480173351322, language=CN, stringName=汪年松, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.上海交通大学附属上海市第六人民医院肾脏内科,上海 200233, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869479397405067, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, xref=2., ext=[AuthorCompanyExt(id=1329869479401599372, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479397405067, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital, Shanghai 200233, China), AuthorCompanyExt(id=1329869479409987981, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479397405067, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海交通大学附属上海市第六人民医院肾脏内科,上海 200233)])])], keywords=[Keyword(id=1329869480454369694, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, language=EN, orderNo=1, keyword=glucagon-like peptide-1 receptor agonist), Keyword(id=1329869480529867167, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, language=EN, orderNo=2, keyword=diabetic nephropathy), Keyword(id=1329869480588587424, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, language=EN, orderNo=3, keyword=oxidative stress), Keyword(id=1329869480706027937, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, language=CN, orderNo=1, keyword=胰高血糖素样肽-1受体激动剂), Keyword(id=1329869480789914018, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, language=CN, orderNo=2, keyword=糖尿病肾病), Keyword(id=1329869480852828579, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, language=CN, orderNo=3, keyword=氧化应激)], refs=[Reference(id=1329869481104486822, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes-2021[J]. Diabetes Care, 2021, 44(Suppl 1): S111-S167., articleTitle=null, refAbstract=null), Reference(id=1329869481179984295, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=郑文, 潘少康, 刘东伟, 等. 糖尿病肾病治疗进展[J]. 中华肾脏病杂志, 2020, 36(6): 476-480., articleTitle=null, refAbstract=null), Reference(id=1329869481259676072, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Sagoo MK, Gnudi L. Diabetic nephropathy: an overview[J]. Methods Mol Biol, 2020, 2067: 3-7., articleTitle=null, refAbstract=null), Reference(id=1329869481326784937, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183: 109119., articleTitle=null, refAbstract=null), Reference(id=1329869481398088106, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=刘东伟, 李征永, 刘章锁. 糖尿病肾病治疗: 立足基点热点、突破靶点焦点[J]. 中华医学杂志, 2021, 101(10): 683-686., articleTitle=null, refAbstract=null), Reference(id=1329869481465196971, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1[J]. Cell Metabolism, 2018, 27(4): 740-756., articleTitle=null, refAbstract=null), Reference(id=1329869481519722924, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Tommerdahl KL, Nadeau KJ, Bjornstad P. Mechanisms of cardiorenal protection of glucagon-like peptide-1 receptor agonists[J]. Adv Chronic Kidney Dis, 2021, 28(4): 337-346., articleTitle=null, refAbstract=null), Reference(id=1329869481599414701, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Smits MM, Van Raalte DH. Safety of semaglutide[J]. Front Endocrinol (Lausanne), 2021, 12: 645563., articleTitle=null, refAbstract=null), Reference(id=1329869481666523566, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Bailey CJ. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk[J]. Lancet Diabetes Endocrinol, 2020, 8(2): 97-99., articleTitle=null, refAbstract=null), Reference(id=1329869481742021039, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409., articleTitle=null, refAbstract=null), Reference(id=1329869481842684336, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Muskiet MHA, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2018, 6(11): 859-869., articleTitle=null, refAbstract=null), Reference(id=1329869481913987505, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang X, Zhang H, Zhang Q, et al. Exenatide and renal outcomes in patients with type 2 diabetes and diabetic kidney disease[J]. Am J Nephrol, 2020, 51(10): 806-814., articleTitle=null, refAbstract=null), Reference(id=1329869481972707762, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet Diabetes Endocrinol, 2019, 7(10): 776-785., articleTitle=null, refAbstract=null), Reference(id=1329869482035622323, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=陆延, 滑瑞雪, 孙玲. 胰高血糖素样肽-1受体激动剂对2型糖尿病患者肾脏预后的荟萃分析[J]. 中国中西医结合肾病杂志, 2022, 23(3): 247-251., articleTitle=null, refAbstract=null), Reference(id=1329869482106925492, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=De Cosmo S, Viazzi F, Pacilli A, et al. Predictors of chronic kidney disease in type 2 diabetes: a longitudinal study from the AMD annals initiative[J]. Medicine (Baltimore), 2016, 95(27): e4007., articleTitle=null, refAbstract=null), Reference(id=1329869482169840053, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Yu JH, Park SY, Lee DY, et al. GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions[J]. Kidney Res Clin Pract, 2022, 41(2): 136-149., articleTitle=null, refAbstract=null), Reference(id=1329869482224366006, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Mali N, Su F, Ge J, et al. Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials[J]. Bio Med Central Endocr Disord, 2022, 22(1): 93., articleTitle=null, refAbstract=null), Reference(id=1329869482291474871, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020[J]. Diabetes Care, 2020, 43(Suppl 1): S14-S31., articleTitle=null, refAbstract=null), Reference(id=1329869482354389432, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Giugliano D, Maiorino MI, Bellastella G, et al. The residual cardiorenal risk in type 2 diabetes[J]. Cardiovasc Diabetol, 2021, 20(1): 36., articleTitle=null, refAbstract=null), Reference(id=1329869482425692601, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Dieter BP, Alicic RZ, Tuttle KR. GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side[J]. Am J Physiol Renal Physiol, 2018, 315(6): F1519-F1525., articleTitle=null, refAbstract=null), Reference(id=1329869482492801466, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Habib HA, Heeba GH, Khalifa MMA. Effect of combined therapy of mesenchymal stem cells with GLP-1 receptor agonist, exenatide, on early-onset nephropathy induced in diabetic rats[J]. Eur J Pharmacol, 2021, 892: 173721., articleTitle=null, refAbstract=null), Reference(id=1329869482551521723, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Abdel-Latif RG, Ahmed AF, Heeba GH. Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats[J]. Life Sci, 2020, 263: 118592., articleTitle=null, refAbstract=null), Reference(id=1329869482614436284, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Ninčević V, Zjalić M, Kolarić TO, et al. Renoprotective effect of liraglutide is mediated via the inhibition of TGF-β1 in an LLC-PK1 cell model of diabetic nephropathy[J]. Curr Issues Mol Biol, 2022, 44(3): 1087-1114., articleTitle=null, refAbstract=null), Reference(id=1329869482677350845, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Li YK, Ma DX, Wang ZM, et al. The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis[J]. Pharmacol Res, 2018, 131: 102-111., articleTitle=null, refAbstract=null), Reference(id=1329869482752848318, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Hendarto H, Inoguchi T, Maeda Y, et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases[J]. Metabolism, 2012, 61(10): 1422-1434., articleTitle=null, refAbstract=null), Reference(id=1329869482815762879, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Victor P, Umapathy D, George L, et al. Crosstalk between endoplasmic reticulum stress and oxidative stress in the progression of diabetic nephropathy[J]. Cell Stress Chaperones, 2021, 26(2): 311-321., articleTitle=null, refAbstract=null), Reference(id=1329869482870288832, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhao XY, Yu TT, Liu S, et al. Effect of liraglutide on endoplasmic reticulum stress in the renal tissue of type 2 diabetic rats[J]. World J Diabetes, 2020, 11(12): 611-621., articleTitle=null, refAbstract=null), Reference(id=1329869482933203393, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Lopez-Sanz L, Bernal S, Recio C, et al. SOCS1-targeted therapy ameliorates renal and vascular oxidative stress in diabetes via STAT1 and PI3K inhibition[J]. Lab Invest, 2018, 98(10): 1276-1290., articleTitle=null, refAbstract=null), Reference(id=1329869482991923650, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Yang X, Liu Q, Li Y, et al. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte ia the AMPK-Sirt1-Pgc-1α signalling pathway[J]. Adipocyte, 2020, 9(1): 484-494., articleTitle=null, refAbstract=null), Reference(id=1329869483050643907, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Zitman-Gal T, Einbinder Y, Ohana M, et al. Effect of liraglutide on the Janus kinase/signal transducer and transcription activator (JAK/STAT) pathway in diabetic kidney disease in db/db mice and in cultured endothelial cells[J]. J Diabetes, 2019, 11(8): 656-664., articleTitle=null, refAbstract=null), Reference(id=1329869483109364164, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Xiao S, Yang Y, Liu YT, et al. Liraglutide regulates the kidney and liver in diabetic nephropathy rats through the miR-34a/SIRT1 pathway[J]. J Diabetes Res, 2021, 2021: 8873956., articleTitle=null, refAbstract=null), Reference(id=1329869483168084421, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Alicic RZ, Cox EJ, Neumiller JJ, et al. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence[J]. Nat Rev Nephrol, 2021, 17(4): 227-244., articleTitle=null, refAbstract=null), Reference(id=1329869483230998982, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Moschovaki Filippidou F, Kirsch AH, Thelen M, et al. Glucagon-like peptide-1 receptor agonism improves nephrotoxic serum nephritis by inhibiting T-cell proliferation[J]. Am J Pathol, 2020, 190(2): 400-411., articleTitle=null, refAbstract=null), Reference(id=1329869483298107847, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang Q, Yang M, Xiao Y, et al. Towards better drug repositioning: targeted immunoinflammatory therapy for diabetic nephropathy[J]. Curr Med Chem, 2021, 28(5): 1003-1024., articleTitle=null, refAbstract=null), Reference(id=1329869483361022408, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Su K, Yi B, Yao BQ, et al. Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis[J]. Pharmacol Res, 2020, 156: 104778., articleTitle=null, refAbstract=null), Reference(id=1329869483436519881, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen S, Yin L, Xu Z, et al. Inhibiting receptor for advanced glycation end product (AGE) and oxidative stress involved in the protective effect mediated by glucagon-like peptide-1 receptor on AGE induced neuronal apoptosis[J]. Neurosci Lett, 2016, 612: 193-198., articleTitle=null, refAbstract=null), Reference(id=1329869483499434442, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Cheng Y, Liu P, Xiang Q, et al. Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway[J]. BMC Musculoskelet Disord, 2022, 23(1): 465., articleTitle=null, refAbstract=null), Reference(id=1329869483579126219, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Frimodt-Møller M, Persson F, Rossing P. Mitigating risk of aldosterone in diabetic kidney disease[J]. Curr Opin Nephrol Hypertens, 2020, 29(1): 145-151., articleTitle=null, refAbstract=null), Reference(id=1329869483654623692, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=von Scholten BJ, Persson F, Rosenlund S, et al. The effect of liraglutide on renal function: a randomized clinical trial[J]. Diabetes Obes Metab, 2017, 19(2): 239-247., articleTitle=null, refAbstract=null), Reference(id=1329869483759481293, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Tanabe J, Ogura Y, Nakabayashi M, et al. The possibility of urinary liver-type fatty acid-binding protein as a biomarker of renal hypoxia in spontaneously diabetic Torii fatty rats[J]. Kidney Blood Press Res, 2019, 44(6): 1476-1492., articleTitle=null, refAbstract=null), Reference(id=1329869483876921806, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhou SJ, Bai L, Lv L, et al. Liraglutide ameliorates renal injury in streptozotocin-induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor-κB pathway[J]. Mol Med Rep, 2014, 10(5): 2587-2594., articleTitle=null, refAbstract=null), Reference(id=1329869483948224975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Yamada S, Tanabe J, Ogura Y, et al. Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats[J]. Clin Exp Nephrol, 2021, 25(4): 365-375., articleTitle=null, refAbstract=null), Reference(id=1329869484015333840, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Vitale M, Haxhi J, Cirrito T, et al. Renal protection with glucagon-like peptide-1 receptor agonists[J]. Curr Opin Pharmacol, 2020, 54: 91-101., articleTitle=null, refAbstract=null), Reference(id=1329869484074054097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial[J]. Lancet Diabetes Endocrinol, 2018, 6(8): 605-617., articleTitle=null, refAbstract=null), Reference(id=1329869484149551570, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Mosterd CM, Bjornstad P, van Raalte DH. Nephroprotective effects of GLP-1 receptor agonists: where do we stand?[J]. J Nephrol, 2020, 33(5): 965-975., articleTitle=null, refAbstract=null), Reference(id=1329869484233437651, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu L, Wang Y, Yan R, et al. BMP-7 inhibits renal fibrosis in diabetic nephropathy via miR-21 downregulation[J]. Life Sci, 2019, 238: 116957., articleTitle=null, refAbstract=null), Reference(id=1329869484308935124, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=Ramzy MM, Abdalla AM, Zenhom NM, et al. Therapeutic effect of liraglutide on expression of CTGF and BMP-7 in induced diabetic nephropathy[J]. J Cell Biochem, 2019, 120(10): 17512-17519., articleTitle=null, refAbstract=null), Reference(id=1329869484371849685, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=Huang L, Lin T, Shi M, et al. Liraglutide suppresses production of extracellular matrix proteins and ameliorates renal injury of diabetic nephropathy by enhancing Wnt/β-catenin signaling[J]. Am J Physiol Renal Physiol, 2020, 319(3): F458-F468., articleTitle=null, refAbstract=null), Reference(id=1329869484443152854, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=Antunes F, Brito PM. Quantitative biology of hydrogen peroxide signaling[J]. Redox Biol, 2017, 13: 1-7., articleTitle=null, refAbstract=null), Reference(id=1329869484535427543, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang G, Fu XL, Wang JJ, et al. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway[J]. J Cell Physiol, 2019, 234(5): 5888-5903., articleTitle=null, refAbstract=null), Reference(id=1329869484602536408, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=Li J, Li N, Yan S, et al. Liraglutide protects renal mesangial cells against hyperglycemia-mediated mitochondrial apoptosis by activating the ERK-Yap signaling pathway and upregulating Sirt3 expression[J]. Mol Med Rep, 2019, 19(4): 2849-2860., articleTitle=null, refAbstract=null), Reference(id=1329869484665450969, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=Winiarska A, Knysak M, Nabrdalik K, et al. Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists[J]. Int J Mol Sci, 2021, 22(19): 10822., articleTitle=null, refAbstract=null), Reference(id=1329869484732559834, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=null, refType=null, unstructuredReference=Xue L, Pan Z, Yin Q, et al. Liraglutide promotes autophagy by regulating the AMPK/mTOR pathway in a rat remnant kidney model of chronic renal failure[J]. Int Urol Nephrol, 2019, 51(12): 2305-2313., articleTitle=null, refAbstract=null), Reference(id=1329869484803863003, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[54], rfOrder=53, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhao X, Liu G, Shen H, et al. Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells[J]. Int J Mol Med, 2015, 35(3): 684-692., articleTitle=null, refAbstract=null), Reference(id=1329869484891943388, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[55], rfOrder=54, authorNames=null, journalName=null, refType=null, unstructuredReference=Yang S, Lin C, Zhuo X, et al. Glucagon-like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway[J]. Am J Physiol Endocrinol Metab, 2020, 319(6): E1019-E1030., articleTitle=null, refAbstract=null)], funds=[Fund(id=1329869480936714660, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, awardId=81770741; 81870504; 82270761, language=CN, fundingSource=国家自然基金面上项目(81770741; 81870504; 82270761), fundOrder=null, country=null), Fund(id=1329869481012212133, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, awardId=null, language=CN, fundingSource=上海市领军人才(058)资助, fundOrder=null, country=null)], companyList=[AuthorCompany(id=1329869479275770248, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, xref=1., ext=[AuthorCompanyExt(id=1329869479305130377, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479275770248, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Macao University of Science and Technology, Macao 999078, China), AuthorCompanyExt(id=1329869479313518986, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479275770248, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.澳门科技大学,澳门 999078)]), AuthorCompany(id=1329869479397405067, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, xref=2., ext=[AuthorCompanyExt(id=1329869479401599372, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479397405067, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital, Shanghai 200233, China), AuthorCompanyExt(id=1329869479409987981, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479397405067, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海交通大学附属上海市第六人民医院肾脏内科,上海 200233)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.01.001, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.01.001, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2023.01.001, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2023.01.001, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1673280000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
胰高血糖素样肽-1受体激动剂治疗糖尿病肾病研究进展
朱轶 1, 2 , 桂定坤 2 , 汪年松 2, *
世界临床药物 | 医药专论 2023,44(1): 1-7
收起
收藏切换
世界临床药物 |医药专论 2023 , 44 (1) : 1 -7
胰高血糖素样肽-1受体激动剂治疗糖尿病肾病研究进展
全屏
[Author(id=1329869479477096847, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869479560982930, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, authorId=1329869479477096847, language=EN, stringName=Yi ZHU, firstName=Yi, middleName=null, lastName=ZHU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.Macao University of Science and Technology, Macao 999078, China
2.Department of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital, Shanghai 200233, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869479640674707, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, authorId=1329869479477096847, language=CN, stringName=朱轶, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.澳门科技大学,澳门 999078
2.上海交通大学附属上海市第六人民医院肾脏内科,上海 200233, bio={"content":"

朱轶,主治医师,博士研究生,研究方向:中西医结合。

"}, bioImg=null, bioContent=

朱轶,主治医师,博士研究生,研究方向:中西医结合。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869479275770248, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, xref=1., ext=[AuthorCompanyExt(id=1329869479305130377, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479275770248, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Macao University of Science and Technology, Macao 999078, China), AuthorCompanyExt(id=1329869479313518986, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479275770248, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.澳门科技大学,澳门 999078)]), AuthorCompany(id=1329869479397405067, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, xref=2., ext=[AuthorCompanyExt(id=1329869479401599372, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479397405067, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital, Shanghai 200233, China), AuthorCompanyExt(id=1329869479409987981, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479397405067, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海交通大学附属上海市第六人民医院肾脏内科,上海 200233)])]), Author(id=1329869479711977877, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329869479925887383, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, authorId=1329869479711977877, language=EN, stringName=Dingkun GUI, firstName=Dingkun, middleName=null, lastName=GUI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital, Shanghai 200233, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869480068493720, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, authorId=1329869479711977877, language=CN, stringName=桂定坤, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.上海交通大学附属上海市第六人民医院肾脏内科,上海 200233, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869479397405067, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, xref=2., ext=[AuthorCompanyExt(id=1329869479401599372, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479397405067, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital, Shanghai 200233, China), AuthorCompanyExt(id=1329869479409987981, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479397405067, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海交通大学附属上海市第六人民医院肾脏内科,上海 200233)])]), Author(id=1329869480173351322, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329869480290791836, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, authorId=1329869480173351322, language=EN, stringName=Niansong WANG, firstName=Niansong, middleName=null, lastName=WANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital, Shanghai 200233, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329869480370483613, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, authorId=1329869480173351322, language=CN, stringName=汪年松, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.上海交通大学附属上海市第六人民医院肾脏内科,上海 200233, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329869479397405067, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, xref=2., ext=[AuthorCompanyExt(id=1329869479401599372, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479397405067, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital, Shanghai 200233, China), AuthorCompanyExt(id=1329869479409987981, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329869478474658181, companyId=1329869479397405067, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.上海交通大学附属上海市第六人民医院肾脏内科,上海 200233)])])]
朱轶1, 2, 桂定坤2, 汪年松2, *
作者信息
  • 1.澳门科技大学,澳门 999078
  • 2.上海交通大学附属上海市第六人民医院肾脏内科,上海 200233
通讯作者:
汪年松,主任医师,教授,博士研究生导师,研究方向:糖尿病肾脏疾病、急性肾损伤的发病机制和防治。
作者简介:

朱轶,主治医师,博士研究生,研究方向:中西医结合。

Research progress on glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy
Yi ZHU1, 2, Dingkun GUI2, Niansong WANG2, *
Affiliations
  • 1.Macao University of Science and Technology, Macao 999078, China
  • 2.Department of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai Sixth People's Hospital, Shanghai 200233, China
出版时间: 2023-01-10 doi: 10.13683/j.wph.2023.01.001
文章导航
收藏切换

胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist,GLP-1RA)是一种新型降糖药物,作用靶点多样,可改善氧化应激、抗炎、减轻晚期糖基化终末产物损害、调节肾素-血管紧张素-醛固酮系统、改善内皮功能以及减轻肾纤维化等,并发挥肾脏保护作用,在临床上被应用于糖尿病肾病(diabetic nephropathy,DN)的治疗。现就近年来发表的关于GLP-1RA治疗DN的临床应用和作用机制的文献进行综述,为临床提供参考。

胰高血糖素样肽-1受体激动剂  /  糖尿病肾病  /  氧化应激

Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a novel hypoglycemic agent with a variety of targets. It is widely used in the treatment of diabetic nephropathy (DN), which is characterized by improving oxidative stress and anti-inflammatory effects, alleviating damage of advanced glycosylation end-products, regulating renin-angiotensin-aldosterone system, improving endothelial function, alleviating renal fibrosis, and playing a protective role in the kidney. This paper reviewed the literatures published in recent years on the clinical application and mechanism of GLP-1RA in the treatment of DN, so as to provide reference for clinical practice.

glucagon-like peptide-1 receptor agonist  /  diabetic nephropathy  /  oxidative stress
朱轶, 桂定坤, 汪年松. 胰高血糖素样肽-1受体激动剂治疗糖尿病肾病研究进展. 世界临床药物, 2023 , 44 (1) : 1 -7 . DOI: 10.13683/j.wph.2023.01.001
Yi ZHU, Dingkun GUI, Niansong WANG. Research progress on glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy[J]. World Clinical Drug, 2023 , 44 (1) : 1 -7 . DOI: 10.13683/j.wph.2023.01.001
  • 国家自然基金面上项目(81770741; 81870504; 82270761)
  • 上海市领军人才(058)资助
参考文献 引证文献
排序方式:
[1]
American Diabetes Association. Microvascular complications and foot care: standards of medical care in diabetes-2021[J]. Diabetes Care, 2021, 44(Suppl 1): S111-S167.
[2]
郑文, 潘少康, 刘东伟, 等. 糖尿病肾病治疗进展[J]. 中华肾脏病杂志, 2020, 36(6): 476-480.
[3]
Sagoo MK, Gnudi L. Diabetic nephropathy: an overview[J]. Methods Mol Biol, 2020, 2067: 3-7.
[4]
Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183: 109119.
[5]
刘东伟, 李征永, 刘章锁. 糖尿病肾病治疗: 立足基点热点、突破靶点焦点[J]. 中华医学杂志, 2021, 101(10): 683-686.
[6]
Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1[J]. Cell Metabolism, 2018, 27(4): 740-756.
[7]
Tommerdahl KL, Nadeau KJ, Bjornstad P. Mechanisms of cardiorenal protection of glucagon-like peptide-1 receptor agonists[J]. Adv Chronic Kidney Dis, 2021, 28(4): 337-346.
[8]
Smits MM, Van Raalte DH. Safety of semaglutide[J]. Front Endocrinol (Lausanne), 2021, 12: 645563.
[9]
Bailey CJ. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk[J]. Lancet Diabetes Endocrinol, 2020, 8(2): 97-99.
[10]
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409.
[11]
Muskiet MHA, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2018, 6(11): 859-869.
[12]
Wang X, Zhang H, Zhang Q, et al. Exenatide and renal outcomes in patients with type 2 diabetes and diabetic kidney disease[J]. Am J Nephrol, 2020, 51(10): 806-814.
[13]
Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J]. Lancet Diabetes Endocrinol, 2019, 7(10): 776-785.
[14]
陆延, 滑瑞雪, 孙玲. 胰高血糖素样肽-1受体激动剂对2型糖尿病患者肾脏预后的荟萃分析[J]. 中国中西医结合肾病杂志, 2022, 23(3): 247-251.
[15]
De Cosmo S, Viazzi F, Pacilli A, et al. Predictors of chronic kidney disease in type 2 diabetes: a longitudinal study from the AMD annals initiative[J]. Medicine (Baltimore), 2016, 95(27): e4007.
[16]
Yu JH, Park SY, Lee DY, et al. GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions[J]. Kidney Res Clin Pract, 2022, 41(2): 136-149.
[17]
Mali N, Su F, Ge J, et al. Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials[J]. Bio Med Central Endocr Disord, 2022, 22(1): 93.
[18]
American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020[J]. Diabetes Care, 2020, 43(Suppl 1): S14-S31.
[19]
Giugliano D, Maiorino MI, Bellastella G, et al. The residual cardiorenal risk in type 2 diabetes[J]. Cardiovasc Diabetol, 2021, 20(1): 36.
[20]
Dieter BP, Alicic RZ, Tuttle KR. GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side[J]. Am J Physiol Renal Physiol, 2018, 315(6): F1519-F1525.
[21]
Habib HA, Heeba GH, Khalifa MMA. Effect of combined therapy of mesenchymal stem cells with GLP-1 receptor agonist, exenatide, on early-onset nephropathy induced in diabetic rats[J]. Eur J Pharmacol, 2021, 892: 173721.
[22]
Abdel-Latif RG, Ahmed AF, Heeba GH. Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats[J]. Life Sci, 2020, 263: 118592.
[23]
Ninčević V, Zjalić M, Kolarić TO, et al. Renoprotective effect of liraglutide is mediated via the inhibition of TGF-β1 in an LLC-PK1 cell model of diabetic nephropathy[J]. Curr Issues Mol Biol, 2022, 44(3): 1087-1114.
[24]
Li YK, Ma DX, Wang ZM, et al. The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis[J]. Pharmacol Res, 2018, 131: 102-111.
[25]
Hendarto H, Inoguchi T, Maeda Y, et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases[J]. Metabolism, 2012, 61(10): 1422-1434.
[26]
Victor P, Umapathy D, George L, et al. Crosstalk between endoplasmic reticulum stress and oxidative stress in the progression of diabetic nephropathy[J]. Cell Stress Chaperones, 2021, 26(2): 311-321.
[27]
Zhao XY, Yu TT, Liu S, et al. Effect of liraglutide on endoplasmic reticulum stress in the renal tissue of type 2 diabetic rats[J]. World J Diabetes, 2020, 11(12): 611-621.
[28]
Lopez-Sanz L, Bernal S, Recio C, et al. SOCS1-targeted therapy ameliorates renal and vascular oxidative stress in diabetes via STAT1 and PI3K inhibition[J]. Lab Invest, 2018, 98(10): 1276-1290.
[29]
Yang X, Liu Q, Li Y, et al. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte ia the AMPK-Sirt1-Pgc-1α signalling pathway[J]. Adipocyte, 2020, 9(1): 484-494.
[30]
Zitman-Gal T, Einbinder Y, Ohana M, et al. Effect of liraglutide on the Janus kinase/signal transducer and transcription activator (JAK/STAT) pathway in diabetic kidney disease in db/db mice and in cultured endothelial cells[J]. J Diabetes, 2019, 11(8): 656-664.
[31]
Xiao S, Yang Y, Liu YT, et al. Liraglutide regulates the kidney and liver in diabetic nephropathy rats through the miR-34a/SIRT1 pathway[J]. J Diabetes Res, 2021, 2021: 8873956.
[32]
Alicic RZ, Cox EJ, Neumiller JJ, et al. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence[J]. Nat Rev Nephrol, 2021, 17(4): 227-244.
[33]
Moschovaki Filippidou F, Kirsch AH, Thelen M, et al. Glucagon-like peptide-1 receptor agonism improves nephrotoxic serum nephritis by inhibiting T-cell proliferation[J]. Am J Pathol, 2020, 190(2): 400-411.
[34]
Zhang Q, Yang M, Xiao Y, et al. Towards better drug repositioning: targeted immunoinflammatory therapy for diabetic nephropathy[J]. Curr Med Chem, 2021, 28(5): 1003-1024.
[35]
Su K, Yi B, Yao BQ, et al. Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis[J]. Pharmacol Res, 2020, 156: 104778.
[36]
Chen S, Yin L, Xu Z, et al. Inhibiting receptor for advanced glycation end product (AGE) and oxidative stress involved in the protective effect mediated by glucagon-like peptide-1 receptor on AGE induced neuronal apoptosis[J]. Neurosci Lett, 2016, 612: 193-198.
[37]
Cheng Y, Liu P, Xiang Q, et al. Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway[J]. BMC Musculoskelet Disord, 2022, 23(1): 465.
[38]
Frimodt-Møller M, Persson F, Rossing P. Mitigating risk of aldosterone in diabetic kidney disease[J]. Curr Opin Nephrol Hypertens, 2020, 29(1): 145-151.
[39]
von Scholten BJ, Persson F, Rosenlund S, et al. The effect of liraglutide on renal function: a randomized clinical trial[J]. Diabetes Obes Metab, 2017, 19(2): 239-247.
[40]
Tanabe J, Ogura Y, Nakabayashi M, et al. The possibility of urinary liver-type fatty acid-binding protein as a biomarker of renal hypoxia in spontaneously diabetic Torii fatty rats[J]. Kidney Blood Press Res, 2019, 44(6): 1476-1492.
[41]
Zhou SJ, Bai L, Lv L, et al. Liraglutide ameliorates renal injury in streptozotocin-induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor-κB pathway[J]. Mol Med Rep, 2014, 10(5): 2587-2594.
[42]
Yamada S, Tanabe J, Ogura Y, et al. Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats[J]. Clin Exp Nephrol, 2021, 25(4): 365-375.
[43]
Vitale M, Haxhi J, Cirrito T, et al. Renal protection with glucagon-like peptide-1 receptor agonists[J]. Curr Opin Pharmacol, 2020, 54: 91-101.
[44]
Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial[J]. Lancet Diabetes Endocrinol, 2018, 6(8): 605-617.
[45]
Mosterd CM, Bjornstad P, van Raalte DH. Nephroprotective effects of GLP-1 receptor agonists: where do we stand?[J]. J Nephrol, 2020, 33(5): 965-975.
[46]
Liu L, Wang Y, Yan R, et al. BMP-7 inhibits renal fibrosis in diabetic nephropathy via miR-21 downregulation[J]. Life Sci, 2019, 238: 116957.
[47]
Ramzy MM, Abdalla AM, Zenhom NM, et al. Therapeutic effect of liraglutide on expression of CTGF and BMP-7 in induced diabetic nephropathy[J]. J Cell Biochem, 2019, 120(10): 17512-17519.
[48]
Huang L, Lin T, Shi M, et al. Liraglutide suppresses production of extracellular matrix proteins and ameliorates renal injury of diabetic nephropathy by enhancing Wnt/β-catenin signaling[J]. Am J Physiol Renal Physiol, 2020, 319(3): F458-F468.
[49]
Antunes F, Brito PM. Quantitative biology of hydrogen peroxide signaling[J]. Redox Biol, 2017, 13: 1-7.
[50]
Wang G, Fu XL, Wang JJ, et al. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway[J]. J Cell Physiol, 2019, 234(5): 5888-5903.
[51]
Li J, Li N, Yan S, et al. Liraglutide protects renal mesangial cells against hyperglycemia-mediated mitochondrial apoptosis by activating the ERK-Yap signaling pathway and upregulating Sirt3 expression[J]. Mol Med Rep, 2019, 19(4): 2849-2860.
[52]
Winiarska A, Knysak M, Nabrdalik K, et al. Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists[J]. Int J Mol Sci, 2021, 22(19): 10822.
[53]
Xue L, Pan Z, Yin Q, et al. Liraglutide promotes autophagy by regulating the AMPK/mTOR pathway in a rat remnant kidney model of chronic renal failure[J]. Int Urol Nephrol, 2019, 51(12): 2305-2313.
[54]
Zhao X, Liu G, Shen H, et al. Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells[J]. Int J Mol Med, 2015, 35(3): 684-692.
[55]
Yang S, Lin C, Zhuo X, et al. Glucagon-like peptide-1 alleviates diabetic kidney disease through activation of autophagy by regulating AMP-activated protein kinase-mammalian target of rapamycin pathway[J]. Am J Physiol Endocrinol Metab, 2020, 319(6): E1019-E1030.
2023年第44卷第1期
14
4
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2023.01.001
  • 接收时间:2022-11-28
  • 首发时间:2026-11-18
  • 出版时间:2023-01-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-11-28
基金
国家自然基金面上项目(81770741; 81870504; 82270761)
上海市领军人才(058)资助
作者信息
    1.澳门科技大学,澳门 999078
    2.上海交通大学附属上海市第六人民医院肾脏内科,上海 200233

通讯作者:

汪年松,主任医师,教授,博士研究生导师,研究方向:糖尿病肾脏疾病、急性肾损伤的发病机制和防治。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.01.001
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏